Company intelligence / Profile preview

Akita Biomedical

Boston, Massachusetts, United Statesakitabiosciences.com ↗

Ownership: Private
Development stage: Commercial

Overview

Akita’s lead product, Profi Nasal Spray, uses a proprietary gel-forming technology to create a physical barrier in the nose that captures and neutralizes airborne contaminants—including viruses like COVID‑19—for several hours. Preclinical studies published in Advanced Materials demonstrate efficacy against respiratory pathogens. The company was named one of Fast Company’s Most Innovative Companies of 2025.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Profi

Commercial

Indications: Respiratory infections, Allergies

Partnerships

Not publicly disclosed

Beyond the preview

Go deeper on Akita Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akita Biomedical.

Explore the full profile